Related Experiment Video
Updated: Jan 23, 2026

Functional Human Liver Preservation and Recovery by Means of Subnormothermic Machine Perfusion
Published on: April 27, 2015
The PI3Kδ inhibitor roginolisib (IOA-244) preserves T-cell function and activity
Elise Solli1,2, Alessio Bevilacqua3, Mathias Wenes4,5
1Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Norway.
Abstract:
PI3K inhibitors (PI3Ki) have shown promise in some hematological cancers, but further development has been hampered by reports of serious immune-related adverse effects. Thus, identification of effective PI3Ki lacking these adverse effects is desirable. Here, we evaluated the in vitro effects of the investigational PI3Ki roginolisib (IOA-244) and the approved PI3Ki idelalisib on immune cells and leukemic cells. Roginolisib inhibited chronic lymphocytic leukemia cell signaling and viability in a manner comparable to idelalisib. Both drugs specifically inhibited PI3K-signaling in T cells, validating their on-target effects. Both idelalisib and roginolisib reduced regulatory T-cell frequency in a concentration-dependent manner, with idelalisib demonstrating greater potency. Both inhibitors also reduced T-cell activation and proliferation, but to differing extents. However, only idelalisib induced a pronounced impairment of CD8+ T-cell cytotoxic function. Furthermore, idelalisib treatment promoted differentiation of conventional CD4+ T cells into Th1, Th2, and Th17 subsets-a response not observed with roginolisib. In summary, roginolisib functions as an effective PI3K inhibitor on leukemic cells while preserving T-cell functions, posing it as an alternative to current PI3K inhibitors.
Insights
Roginolisib effectively targets leukemia cells like idelalisib but better preserves T-cell functions. This PI3K inhibitor may offer a safer alternative for hematological cancer treatment.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Phosphoinositide 3-kinase inhibitors (PI3Ki) show promise in hematological cancers.
- Serious immune-related adverse effects limit current PI3Ki development.
- Novel PI3Ki with improved safety profiles are needed.
Purpose of the Study:
- Evaluate the in vitro effects of roginolisib (IOA-244) and idelalisib on immune and leukemic cells.
- Compare the efficacy and safety profiles of these two PI3K inhibitors.
- Identify potential alternatives to current PI3Ki with reduced immunotoxicity.
Main Methods:
- In vitro assessment of roginolisib and idelalisib.
- Evaluation of effects on chronic lymphocytic leukemia cells.
- Analysis of T-cell signaling, activation, proliferation, and cytotoxic function.
Main Results:
- Both roginolisib and idelalisib inhibited leukemic cell signaling and viability.
- Both drugs demonstrated on-target PI3K inhibition in T cells.
- Roginolisib preserved T-cell functions, including cytotoxic activity and differentiation, unlike idelalisib.
- Idelalisib showed greater potency in reducing regulatory T-cell frequency but impaired CD8+ T-cell function.
Conclusions:
- Roginolisib is an effective PI3K inhibitor for leukemic cells.
- Roginolisib preserves critical T-cell functions, unlike idelalisib.
- Roginolisib represents a promising alternative PI3K inhibitor with a potentially improved safety profile for hematological cancers.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Dipeptidyl Peptidase 4 Inhibitors
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Antihypertensive Drugs: Direct Renin Inhibitors

